Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUTL Autolus Therapeutics	$2.41 -0.4%	$2.04	$1.11 ▼ $5.00	$641.40M	1.81	1.57 million shs	1.50 million shs
CABA Cabaletta Bio	$1.67 -0.6%	$1.79	$0.99 ▼ $7.28	$84.74M	2.7	1.68 million shs	622,840 shs
CASI CASI Pharmaceuticals	$1.26 -2.3%	$1.60	$1.09 ▼ $7.67	$15.50M	0.53	48,193 shs	15,904 shs
EIGR Eiger BioPharmaceuticals		$4.35	$1.10 ▼ $43.35	$2.55M	1.83	103,866 shs	137,800 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUTL Autolus Therapeutics	0.00%	-2.43%	+16.99%	+68.53%	-45.60%
CABA Cabaletta Bio	0.00%	-4.02%	-3.47%	+51.82%	-77.91%
CASI CASI Pharmaceuticals	0.00%	-10.00%	-7.35%	-37.62%	-79.97%
EIGR Eiger BioPharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AUTL Autolus Therapeutics	2.7062 of 5 stars	3.5	1.0	0.0	0.0	2.5	3.3	0.6
CABA Cabaletta Bio	2.8801 of 5 stars	3.5	4.0	0.0	0.0	2.6	0.8	0.6
CASI CASI Pharmaceuticals	3.7021 of 5 stars	3.5	3.0	0.0	4.3	0.6	1.7	0.0
EIGR Eiger BioPharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUTL Autolus Therapeutics	3.00	Buy	$9.32	286.72% Upside
CABA Cabaletta Bio	3.00	Buy	$14.43	763.99% Upside
CASI CASI Pharmaceuticals	3.00	Buy	$4.00	217.46% Upside
EIGR Eiger BioPharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest CASI, EIGR, AUTL, and CABA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	AUTL Autolus Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/11/2025	CABA Cabaletta Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
5/19/2025	CASI CASI Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
5/16/2025	CABA Cabaletta Bio	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $13.00
5/15/2025	CABA Cabaletta Bio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$23.00 ➝ $25.00

(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUTL Autolus Therapeutics	$10.12M	63.38	N/A	N/A	$1.61 per share	1.50
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	$3.12 per share	N/A
CASI CASI Pharmaceuticals	$28.54M	0.54	N/A	N/A	$0.12 per share	10.50
EIGR Eiger BioPharmaceuticals	$15.77M	0.00	N/A	N/A	$37.68 per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUTL Autolus Therapeutics	-$220.66M	-$0.88	N/A	N/A	N/A	N/A	-52.82%	-29.67%	8/14/2025 (Estimated)
CABA Cabaletta Bio	-$115.86M	-$2.54	N/A	N/A	N/A	N/A	-78.29%	-65.68%	8/6/2025 (Estimated)
CASI CASI Pharmaceuticals	-$39.26M	-$2.55	N/A	∞	N/A	-129.05%	-972.55%	-77.33%	8/15/2025 (Estimated)
EIGR Eiger BioPharmaceuticals	-$96.78M	-$59.16	N/A	N/A	N/A	-590.80%	-332.49%	-99.77%	N/A

Latest CASI, EIGR, AUTL, and CABA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/15/2025	N/A	CASI CASI Pharmaceuticals	-$0.47	N/A	N/A	N/A	$6.28 million	N/A
8/14/2025	Q2 2025	AUTL Autolus Therapeutics	-$0.2329	N/A	N/A	N/A	$12.92 million	N/A
8/14/2025	Q2 2025	CABA Cabaletta Bio	-$0.71	N/A	N/A	N/A	N/A	N/A
5/21/2025	Q1 2025	CABA Cabaletta Bio	-$0.67	-$0.71	-$0.04	-$0.71	N/A	N/A
5/16/2025	Q1 2025	CASI CASI Pharmaceuticals	-$0.61	-$0.69	-$0.08	-$0.69	$7.39 million	$6.24 million
5/8/2025	Q1 2025	AUTL Autolus Therapeutics	-$0.24	-$0.26	-$0.02	-$0.26	$1.59 million	$8.98 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUTL Autolus Therapeutics	N/A	N/A	N/A	N/A	N/A
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	N/A
CASI CASI Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
EIGR Eiger BioPharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUTL Autolus Therapeutics	N/A	9.24	9.02
CABA Cabaletta Bio	N/A	3.96	3.96
CASI CASI Pharmaceuticals	N/A	0.81	0.68
EIGR Eiger BioPharmaceuticals	N/A	3.31	3.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AUTL Autolus Therapeutics	72.83%
CABA Cabaletta Bio	N/A
CASI CASI Pharmaceuticals	22.23%
EIGR Eiger BioPharmaceuticals	62.46%

Insider Ownership

Company	Insider Ownership
AUTL Autolus Therapeutics	25.70%
CABA Cabaletta Bio	11.25%
CASI CASI Pharmaceuticals	21.24%
EIGR Eiger BioPharmaceuticals	4.22%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AUTL Autolus Therapeutics	330	266.14 million	197.74 million	Optionable
CABA Cabaletta Bio	50	50.74 million	45.03 million	Optionable
CASI CASI Pharmaceuticals	180	12.30 million	9.69 million	Optionable
EIGR Eiger BioPharmaceuticals	56	1.48 million	1.42 million	Optionable

CASI, EIGR, AUTL, and CABA Headlines

Recent News About These Companies

Two die in Eiger avalanche

May 20, 2025 | worldradio.chW

New Route On Eiger's North Face Will Have to Wait

April 16, 2025 | msn.com

RigiTech Eiger is reaching SAIL III, opening new horizons for drone logistics

April 10, 2025 | suasnews.comS

Eiger hosts Gelato Masterclass in Sri Lanka

March 28, 2025 | dailymirror.lkD

Remembering John Harlin, Eiger Legend

March 23, 2025 | msn.com

Eiger Trail

November 2, 2024 | myswitzerland.comM

The role of lactate in the exercise-induced human growth hormone response: evidence from McArdle disease

October 30, 2024 | bjsm.bmj.comB

Eiger BioPharmaceuticals Inc (OTC:EIGRQ) Stock Quotes, Forecast and News Summary

October 6, 2024 | benzinga.com

Climbing the iconic Eiger mountain in Switzerland

October 4, 2024 | swissinfo.chS

Eiger Biopharmaceuticals Inc (EIGRQ)

September 29, 2024 | investing.com

Massive Rockfall on the North Face of the Eiger

September 8, 2024 | yahoo.com

Former NFL Player Mark Pattison Tackles The Eiger

September 2, 2024 | si.comS

Eiger BioPharmaceuticals gets grant for combination treatment for hepatitis delta virus (hdv) infection

August 24, 2024 | pharmaceutical-technology.comP

Eiger BioPharmaceuticals, Inc. (EIGRQ)

August 13, 2024 | finance.yahoo.com

72C.SG,0P00015QPW,0 (72C.SG)

August 3, 2024 | ca.finance.yahoo.com

SKYY Network and MedLife Use Eiger Drones to Transport STD Tests Collected at Electric Castle, Providing Same-Day Results Directly in the App

July 29, 2024 | suasnews.comS

Polkadot Welcomes Move: Eiger Completes Integration for Substrate Blockchains.

July 26, 2024 | crypto-news-flash.comC

SSG Advises Eiger BioPharmaceuticals in Sale of Avexitide Program Assets to Amylyx Pharmaceuticals

July 19, 2024 | abladvisor.comA

Sentynl acquires Eiger’s Zokinvy for progeria treatment

May 6, 2024 | pharmaceutical-technology.comP

Sentynl, a Zydus Group company acquires Zokinvy to treat Hutchinson-Gilford progeria syndrome from Eiger BioPharma

May 6, 2024 | pharmabiz.comP

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
3 Semiconductor Stocks Poised to Surge on AI Spending
By Chris Markoch | June 25, 2025
View 3 Semiconductor Stocks Poised to Surge on AI Spending
Astera Labs: AI Infrastructure Play With Significant Growth Ahead
By Nathan Reiff | June 26, 2025
View Astera Labs: AI Infrastructure Play With Significant Growth Ahead

CASI, EIGR, AUTL, and CABA Company Descriptions

Autolus Therapeutics NASDAQ:AUTL

$2.41 -0.01 (-0.41%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$2.40 -0.01 (-0.21%)

As of 07/18/2025 06:41 PM Eastern

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Cabaletta Bio NASDAQ:CABA

$1.67 -0.01 (-0.60%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$1.68 +0.02 (+0.90%)

As of 07/18/2025 07:50 PM Eastern

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

CASI Pharmaceuticals NASDAQ:CASI

$1.26 -0.03 (-2.33%)

Closing price 07/18/2025 03:59 PM Eastern

Extended Trading

$1.27 +0.01 (+0.48%)

As of 07/18/2025 05:00 PM Eastern

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

Eiger BioPharmaceuticals NASDAQ:EIGR

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time